SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 8,500 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $7.66, for a total value of $65,110.00. Following the completion of the transaction, the chairman owned 3,435,822 shares in the company, valued at approximately $26,318,396.52. This represents a 0.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.61, for a total transaction of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.23, for a total transaction of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total transaction of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total value of $290,400.20.

SOPHiA GENETICS Stock Down 0.1%

Shares of SOPH opened at $7.86 on Tuesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 52 week low of $3.12 and a 52 week high of $8.98. The stock has a market capitalization of $659.38 million, a price-to-earnings ratio of -6.83 and a beta of 0.98. The stock has a fifty day moving average of $7.08 and a 200-day moving average of $5.71.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently bought and sold shares of the company. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS during the 2nd quarter worth about $9,809,000. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the 1st quarter worth about $2,157,000. Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $2,009,000. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. Finally, 1492 Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at about $973,000. Institutional investors own 31.59% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright increased their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.